Specific and associated autoantibodies in polymyositis and dermatomyositis

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991; 325: 1478–98.

2. Al-Lozi M, Pestronk A. Organ-specific autoantibodies with muscle weakness. Curr Opin Rheumatol 1999; 11: 483–8.

3. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Tonello M, Bendo R, et al. Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients]. Reumatismo 2005; 57: 22–8.

4. Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 2006; 39: 217–21.

5. Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007; 56: 1295–303.

6. Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007; 34: 1012–8.

7. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991: 70: 360–74.

8. Targoff IN, Arnett FC, Reichlin M. Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum 1988; 31: 515–24.

9. Karsten C, Werner S, Falk H, Fritzer MJ. Autoantibodies in systemic autoimmune diseases-a diagnostic reference. Pabs Scientific publishers. Berlin. 2007. 2nd edition.

10. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56: 3125–31.

11. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49–54.

12. Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54: 2004–9.

13. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990; 88: 241–51.

14. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992; 35: 821–30.

15. Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162: 2315–20.

16. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patinets with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology 2007; 46: 842–5.

17. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007; 46: 1005–8.

18. Hengstman GJ, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patiens; myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002; 249: 69–75.

19. Targof IN, Johnson AE, Miller FW. Antibody signal recognition particle in polymyositis. Arthritis Rheum 1990; 33: 1361–70.

20. Hengstman GJ, Ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-SRP autoantibodies, marker of a necrotizing myopathy. Ann Rheum Dis 2006; 65: 1635–8.

21. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to be the signal recognition particle: clinical pathological features. J Neurol Neurosurg Psychiatric 2002; 73: 420–8.

22. Leff RL, Burgess SH, Miller FW, Love LA, Targoff IN, Dalakas MC, et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum 1991; 34: 1391–6.

23. Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001; 29: 2517–21.

24. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in trascriptional activation. Arthritis Rheum 1995; 38: 1389–99.

25. Ge Q, Nilasena DS, O‘Brien CA, Frank MB, Targoff IN. Molecular analysis of a major antigenic region of the 240-kDa protein of Mi-2 autoantigen. J Clin Invest 1995; 96: 1730–7.

26. Seelig HP, Renz M, Targoff IN, Ge Q, Frank MB. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum 1996; 39: 1769–71.

27. Hengstman GJD, Vree Egberts WTM, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2‚ antigen. Ann Rheum Dis 2006; 65: 242–5.

28. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A. Anti-Mi-2 antibodies. Autoimmunity. 2005; 38: 79–83.

29. Selva-O‘Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006; 55: 791–8.

30. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–6.

31. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46: 25–8.

32. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O‘Hanlon TP, Miller FW, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 3682–9.

33. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47: 324–8.

34. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66: 1345–9.

35. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19: 523–9.

36. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132–7.

37. Arad-Dann H, Isenberg D, Ovadia E, Shoenfeld Y, Sperling J, Sperling R. Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. J Autoimmun 1989; 2: 877–88.

38. Blüthner M, Bautz FA. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med 1992; 176: 973–80.

39. Raijmakers R, Renz M, Wiemann C, Egberts WV, Seelig HP, van Venrooij WJ, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004; 50: 565–9.

40. Mahler M, Raijmakers R, Dähnrich C, Blüthner M, Fritzler MJ. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005; 7: R704–13.

41. Mimori T, Hardin JA, Steitz JA. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem 1986; 261: 2274–8.

42. Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airė P, Cattaneo R, et al. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus 2008; 17: 727–32.

43. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9: R78.

44. Vencovský J, Williams DG, Field M, Maini RN. Clinical associations of IgG antibodies to the RNP p-67 polypeptide in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 1313–17.

45. Coppo P, Clauvel JP, Bengoufa D, Oksenhendler E, Lacroix C, Lassoued K. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology (Oxford) 2002; 41: 1040–6.

46. Feist E, Dörner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, et al. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996; 184: 1313–8.

47. Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006; 339: 415–21.

48. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patinets with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109: 32–40.

49. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 1999 Mar; 12(2): 137–142.

50. Kajihara M, Kuwana M, Tokuda H, Yamane K, Kubo M, Hirakata M, et al. Myositis and interstitial lung dinase associated with autoantibody to a transfer RNA-related protein Wa. J Rheumatol 2000; 27: 2707–10.

51. Casciola-Rosen LA, Pluta AF, Plotz PH, Cox AE, Morris S, Wigley FM, et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001; 44: 389–96.

52. Staněk D, Vencovský J, Kafková J, Raška I. Heterogenous nuclear ribonucleoprotein (hnRNP) C1 a C2 „core“ proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. Arthritis Rheum 1997; 40: 2172–7.

53. Heegaard NH, Larsen MR, Muncrief T, Wiik A, Roepstorff P. Heterogeneous nuclear ribonucleoproteins C1/C2 identified as autoantigens by biochemic and mass spectrometric methods. Arthritis Rheum 2000, 2: 407–14.

54. Schilders G, Vree Egberts W, Raijimakers R, Pruijn GJM. C1D is a major antoantibody target in patients with the polymyositis-scleroderma overlap syndrome. Arthritis Rheum 2007; 56: 2449–54.

55. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum 1997; 40: S139.

56. Mimura Y, Yazawa N, Tamaki Z, Ashida R, Jinnin M, Asano Y, et al. Anti-p53 antibodies in patients with dermatomyositis/polymyositis. Clin Rheumatol 2007; 26: 1328–31.

57. Targoff IN, Arnett FC, Berman L, O‘Brien C, Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest 1989; 84: 162–72.